Abstract
A series of di-indolinone derivatives was designed and synthesized to optimize our lead compounds basing on molecular docking study as PTP1B inhibitors. Successive enzymatic assay identified the synthetic di-indolinone as novel PTP1B inhibitors with low micromole-ranged inhibitory activity and at least several-fold selectivity over other tested homologous PTPs.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Indoles / chemical synthesis
-
Indoles / chemistry
-
Indoles / pharmacology*
-
Models, Molecular
-
Molecular Structure
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors*
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
-
Structure-Activity Relationship
Substances
-
Enzyme Inhibitors
-
Indoles
-
PTPN1 protein, human
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1